Merck Healthcare KGaA — Sponsor Intelligence | 27 EU Trials

Filter these 27 trials by condition, phase, country and more.

Open in Search →

27 Registered trials

5 Recruiting

20 Completed trials

16 Countries active

14 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase III: 3 Phase II: 6 Phase I/II: 4 Phase I: 5 Phase I (Other): 9

Oversight events:

5 temporary halts 1 urgent safety measure 1 corrective measure across 6 trials

View oversight register →

100%

20 of 20 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer metastatic 1 Soft tissue sarcoma 1 Dermatomyositis 1 Infertility female 1 Non-small cell lung cancer 1 Polymyositis 1 Glioblastoma 1 Pancreatic carcinoma metastatic 1 Triple negative breast cancer 1 Gastric cancer 1 Myasthenia gravis 1 Ovarian epithelial cancer 1

Top IMPs

ENPATORAN 3 PRECEMTABART TOCENTECAN 3 2-AMINO-6-FLUORO-N-(5-FLUORO-4-(1-METHYL-1H-IMIDAZOL-5-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE 2 AVELUMAB 2 TEPOTINIB 2 8-(1,3-DIMETHYLPYRAZOL-4-YL)-1-(3-FLUORO-5-METHOXYPYRIDIN-4-YL)-7-METHOXY-3-METHYLIMIDAZO[4,5-C]QUINOLIN-2-ONE 1 CEMIPLIMAB 1 CLADRIBINE 1 LENVATINIB 1 NIRAPARIB TOSILATE MONOHYDRATE 1 OSIMERTINIB 1 RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E 1

All trials

27 total

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors Pending

2025-523232-39-00 Phase I 1 country
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC) Recruiting

2024-517819-74-00 Phase I/II 5 countries PRECEMTABART TOCENTECAN
Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla… Recruiting

2023-507746-83-00 Phase III 12 countries CLADRIBINE; RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors Recruiting

2022-500508-23-00 Phase I 2 countries
Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants Recruiting

2024-513069-37-00 Phase I 1 country
Anti-GD2 ADC M3554 in Advanced Solid Tumors Recruiting

2024-513687-26-00 Phase I 2 countries
Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended

2024-517817-34-00 Phase I/II 5 countries PRECEMTABART TOCENTECAN
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended

2024-517818-15-00 Phase I/II 5 countries PRECEMTABART TOCENTECAN
M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501) Ended

2024-513492-41-00 Phase I (Other) 1 country
Tuvusertib Combined with Niraparib or Lartesertib in Participants with Epithelial Ovarian Cancer (DDRiver EOC 302) Ended

2024-511202-23-00 Phase II 8 countries 2-AMINO-6-FLUORO-N-(5-FLUORO-4-(1-METHYL-1H-IMIDAZOL-5-YL)PYRIDIN-3-YL)PYRAZOLO[…
Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322) Ended

2022-502010-85-00 Phase I/II 5 countries 2-AMINO-6-FLUORO-N-(5-FLUORO-4-(1-METHYL-1H-IMIDAZOL-5-YL)PYRIDIN-3-YL)PYRAZOLO[…
The WILLOW LTE study with enpatoran in participants with SCLE, DLE and/or SLE Ended

2024-510871-39-00 Phase II 5 countries ENPATORAN
Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) Ended

2024-515848-23-00 Phase I 1 country
Avelumab Program Rollover Study Ended

2024-514274-46-00 Phase III 7 countries AVELUMAB
Study of Avelumab in combination with Lenvatinib for children with primary CNS tumors Halted

2024-512940-51-00 Phase I (Other) 2 countries AVELUMAB; LENVATINIB
M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) Ended

2024-514155-15-00 Phase I (Other) 1 country
A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants Ended

2024-512841-17-00 Phase I (Other) 1 country
Effect of Renal Impairment on Enpatoran Pharmacokinetics Ended

2024-513393-22-00 Phase I (Other) 1 country
A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa… Ended

2023-507066-91-00 Phase I (Other) 1 country
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) Ended

2022-502940-10-00 Phase I (Other) 1 country
Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN Ended

2023-505796-76-00 Phase I (Other) 2 countries
Study of M5049 in DM and PM Participants (NEPTUNIA) Ended

2022-501351-82-00 Phase II 6 countries ENPATORAN
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended

2023-508528-36-00 Phase III 12 countries XEVINAPANT
Study of tuvusertib (M1774) in combination with DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors Ended

2022-500287-35-00 Phase I (Other) 1 country

Showing 1–24 of 27 trials

← All sponsors A–Z